HEIDELBERG, Germany--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CyclASol?src=hash" target="_blank"gt;#CyclASollt;/agt;--Novaliq, the pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on the water-free EyeSol® technology, has been named a finalist in “Clinical Trial Result of the Year” category of the CARE Awards, which recognizes outstanding work across the global clinical research enterprise. In 2018, Novaliq conducted...
Tue Feb 26, 2019 09:00
As per the terms of the merger agreement, Roche will buy each share of Spark Therapeutics at a price of $114.50. Founded in 2013, Spark Therapeutics is engaged The post Roche to acquire gene therapy company Spark Therapeutics for $4.3bn appeared first on Pharmaceutical Business review.
Tue Feb 26, 2019 09:12
Danaher seeks to help its customers solve complex challenges and enhance quality of life across the world. GE Biopharma offers instruments, consumables, and software to facilitate research, discovery, The post Danaher agrees to buy GE’s biopharma business for $21.4bn appeared first on Pharmaceutical Business review.
Tue Feb 26, 2019 09:12
Through the transaction, Ipsen will acquire Clementia’s key late-stage clinical asset palovarotene, which is an investigational retinoic acid receptor gamma (RARγ) selective agonist. Palovarotene is being developed for The post Ipsen to buy rare-disease drug maker Clementia in $1.3bn deal appeared first on Pharmaceutical Business review.
Tue Feb 26, 2019 09:12
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a public offering price of $150.00 per share. The gross proceeds to Sage Therapeutics from the offering, before deducting the underwriting discounts and commissions and other estimated offerin
Tue Feb 26, 2019 04:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4, 2019 at 8:00 a.m. EST to review operating results for the fourth quarter and full year ended December 31, 2018 and new, preliminary analyses from the Phase 3 VISTA trial of Vicinium® for patients with high-risk non-musc
Mon Feb 25, 2019 23:20
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
Mon Feb 25, 2019 23:15
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter and Full Year 2018 Financial Results under ASC 606 Revenue for the three and twelve months ended December 31, 2018 was $192.1 million and $704.6 million, respectively. Backlog as of December 31, 2018 was $1.1 billion and net new business awards were $231.2 million, representing a net book-to-bill ratio of 1.
Mon Feb 25, 2019 23:15
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and full year ended December 31, 2018. Recent Business Highlights In December 2018, the company commenced enrollment in the study of its newest platform product, the ASCEND investigational drug-coated sinus balloon. This novel device is designed to deliver a corticos
Mon Feb 25, 2019 23:05
BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announced financial results for the full year 2018.
Mon Feb 25, 2019 23:05
Diabetic Gastroparesis StudyDiabetic gastroparesis creates feelings of bloating, nausea, vomiting and pain. If you have diabetes, ClinSearch is enrolling volunteers in a study testing an investigational medication.
Mon Feb 25, 2019 00:00
NEUCHATEL, Zwitserland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) maakte vandaag de bevindingen bekend van een reeks van vier klinische cases, onlangs gepubliceerd in het Canadese Journal of Anesthesiology, waarin onderzoekers van de Universiteit van Montreal ontdekten dat het gecombineerde gebruik van Masimo SedLine® hersenfunctiebewaking en O3® regionale oximetrie hun begrip en beheer van cerebrale desaturaties tijdens hartchirurgie ondersteunde. Drs. Etienne Couture, Alain Deschamps en André De
Mon Feb 25, 2019 20:02
NEUCHÂTEL, Svizzera--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) ha reso noti oggi i risultati di una serie di quattro studi clinici, recentemente pubblicati sul Canadian Journal of Anesthesiology, in cui i ricercatori dell’Università di Montreal mostrano come l’impiego combinato del monitoraggio della funzione cerebrale SedLine® e dell’ossimetria regionale O3® di Masimo abbia contribuito a una migliore comprensione e gestione delle desaturazioni cerebrali durante gli interventi di cardiochirurgia.
Mon Feb 25, 2019 20:02
DUBLIN--(BUSINESS WIRE)--The "Cancer Diagnostics Market Analysis Report By Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), By Application (Breast, Lung, Liver, Cervical, Colorectal, Skin), By Region, And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering. The global cancer diagnostics market size is expected to reach USD 249.6 billion by 2026, exhibiting a 7% CAGR during the forecast period. Continual introduction of innovative products, coupl
Mon Feb 25, 2019 19:34
Do you have uncontrolled type 2 diabetes? Full management of type 2 diabetes using antidiabetic oral medications (OADs) can be frustrating and time consuming. The Revita System is a potential new type 2 diabetes treatment procedure that is not a pill or an injection. Based on new discoveries in metabolic science, the investigational Revita™ duodenal mucosal resurfacing (DMR) procedure targets the upper intestine, or duodenum, with the aim of addressing a root cause of insulin resistance in type...
Mon Feb 25, 2019 00:00
Do you have uncontrolled type 2 diabetes? Full management of type 2 diabetes using antidiabetic oral medications (OADs) can be frustrating and time consuming. The Revita System is a potential new type 2 diabetes treatment procedure that is not a pill or an injection. Based on new discoveries in metabolic science, the investigational Revita™ duodenal mucosal resurfacing (DMR) procedure targets the upper intestine, or duodenum, with the aim of addressing a root cause of insulin resistance in type...
Mon Feb 25, 2019 00:00
DUBLIN--(BUSINESS WIRE)--The "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Anaplastic Thyroid Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Anaplastic Thyroid Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Anaplastic Thyroid Cancer. Report includes an overview of trial numbers and their average enrollment in top countries c
Mon Feb 25, 2019 18:00
This is a 1-Hour Usability Research Study for Parents and their Teen (ages 12-17) who have been Diagnosed with one of 3 types of JAWe are currently seeking participants to take part in a Usability Study being sponsored by a major medical company. The study will take place in mid-March and will require a parent or legal guardian to accompany the teen to and during the 1-hour study. Same day payment for this study is: $150 for the teen and $100 for the parent.The Study is to evaluate the usability...
Sun Feb 24, 2019 00:00
WASHINGTON, DC--(BUSINESS WIRE)--The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today launches its nationwide “Fight Back Give Back” campaign to highlight the importance of clinical trials in driving progress towards curing disease. “Too many patients never consider participating in clinical trials or else too often wait until they have few if any other options,” said MRA President and CEO Michael Kaplan. “However, for many patients, clinical trials re
Mon Feb 25, 2019 16:30
米マサチューセッツ州ダンバース--(BUSINESS WIRE)--（ビジネスワイヤ） -- アビオメッド（NASDAQ: ABMD）は科学研究上の重要な実績として、過去5年間にわたり1億ドル以上をImpella心臓ポンププラットフォームの臨床研究に投資してきました。臨床研究に対するアビオメッドのコミットメントについては、本日開設した新しいウェブページで詳細に説明しています。 アビオメッドがスポンサーとなっている研究は、20年にわたる独立の医師主導型研究イニシアチブと、計550本以上の査読学術論文によって充実したものとなっています。それらの研究により、Impellaの血行力学的利点、すなわち左心室を直接アンロードし、心機能を回復するという利点が確認されています。その結果、Impellaは8本の臨床ガイドラインに掲載されており¹、欧州のCEマーク、日本のPMDA、米国食品医薬品局による最高レベルの規制承認であるPMAを含む規制承認を取得しています。 今日までにアビオメッドの臨床研究に対するコミットメントは、下記の実績に貢献しています。 医療機器業界の市販後調査として最も完全かつ大規模な
Mon Feb 25, 2019 16:1
ETOY, Switzerland--(BUSINESS WIRE)--Sunstar Suisse SA announces its acquisition from BMG Pharma S.p.A. of GelX® for the treatment and prevention of oral mucositis.
Mon Feb 25, 2019 16:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company presented Phase 2 clinical data and preclinical research on its MGTA-456 program at the TCT annual meeting. MGTA-456 is a cell therapy designed to provide a high dose of hematopoietic stem cells that are well-matched to the patient. The Company plans to enrol
Mon Feb 25, 2019 15:15
DUBLIN--(BUSINESS WIRE)--The "Aphthous Ulcers (Canker Sores) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Aphthous Ulcers (Canker Sores) Global Clinical Trials Review, H2, 2018" provides an overview of Aphthous Ulcers (Canker Sores) clinical trials scenario. This report provides top line data relating to the clinical trials on Aphthous Ulcers (Canker Sores). Report includes an overview of trial numbers and their average enrollmen
Mon Feb 25, 2019 14:49
DUBLIN--(BUSINESS WIRE)--The "Seminar on Phase I GMPs" conference has been added to ResearchAndMarkets.com's offering. Early clinical trials are conducted to establish initial safety of a drug. The studies are generally in small number of healthy subjects and use lower doses of the drug product. Therefore, only small amounts of investigational material are required. In order to not undertake substantial costs and to reduce regulatory burden during these early stages, the FDA has established gui
Mon Feb 25, 2019 14:44
DUBLIN--(BUSINESS WIRE)--The "Alzheimer's Disease Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Alzheimer's Disease Global Clinical Trials Review, H2, 2018" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the glob
Mon Feb 25, 2019 14:41
DUBLIN--(BUSINESS WIRE)--The "Anthrax Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Anthrax Global Clinical Trials Review, H2, 2018" provides an overview of Anthrax clinical trials scenario. This report provides top line data relating to the clinical trials on Anthrax. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinica
Mon Feb 25, 2019 14:40
DUBLIN--(BUSINESS WIRE)--The "Aortic Aneurysm Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Aortic Aneurysm Global Clinical Trials Review, H2, 2018" provides an overview of Aortic Aneurysm clinical trials scenario. This report provides top line data relating to the clinical trials on Aortic Aneurysm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report of
Mon Feb 25, 2019 14:38
DUBLIN--(BUSINESS WIRE)--The "Ancylostomiasis (Hookworm Infections) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Ancylostomiasis (Hookworm Infections) Global Clinical Trials Review, H2, 2018" provides an overview of Ancylostomiasis (Hookworm Infections) clinical trials scenario. This report provides top line data relating to the clinical trials on Ancylostomiasis (Hookworm Infections). Report includes an overview of trial numbers
Mon Feb 25, 2019 14:01
WILMINGTON, Del.--(BUSINESS WIRE)--The Phase III THEMIS trial met its primary endpoint which demonstrated that BRILINTA® (ticagrelor) tablets, taken in conjunction with aspirin, showed a statistically-significant reduction in major adverse cardiovascular events (MACE, a composite of cardiovascular death, heart attack and stroke) compared to aspirin alone. THEMIS was conducted in over 19,000 patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior heart attack or strok
Mon Feb 25, 2019 14:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Enobio?src=hash" target="_blank"gt;#Enobiolt;/agt;--At the recent American Epilepsy Society Annual Meeting in New Orleans, Neuroelectrics Corporation presented positive results from its clinical trial treating patients with drug resistant epilepsy with Starstim™, a device that uses mild electric currents applied on the scalp to calm abnormal activity of the brain. Of the seventeen patients that completed the study, treatment...
Mon Feb 25, 2019 14:00
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure Announces Dosing of First Patient in Phase 1b/2 Immuno-oncology Trial
Mon Feb 25, 2019 14:00
BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc. (Nasdaq:ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with Proteus syndrome. These data, together with data already presented at ASHG last year, support miransertib’s further development as a potential first systemic...
Mon Feb 25, 2019 14:00
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the expansion of its distribution agreement with Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) in South Korea, for the indication of non-alcoholic steatohepatitis (NASH). CKD will receive exclusive rights to distribute Namod
Mon Feb 25, 2019 14:00
DUBLIN--(BUSINESS WIRE)--The "Androgenic Alopecia Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Androgenic Alopecia Global Clinical Trials Review, H2, 2018" provides an overview of Androgenic Alopecia clinical trials scenario. This report provides top line data relating to the clinical trials on Androgenic Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the glob
Mon Feb 25, 2019 13:55
DUBLIN--(BUSINESS WIRE)--The "Aneurysm Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Aneurysm Global Clinical Trials Review, H2, 2018" provides an overview of Aneurysm clinical trials scenario. This report provides top line data relating to the clinical trials on Aneurysm. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease cli
Mon Feb 25, 2019 13:47
DUBLIN--(BUSINESS WIRE)--The "Angioedema Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Angioedema Global Clinical Trials Review, H2, 2018" provides an overview of Angioedema clinical trials scenario. This report provides top line data relating to the clinical trials on Angioedema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of dis
Mon Feb 25, 2019 13:33
DUBLIN--(BUSINESS WIRE)--The "Angiosarcoma Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Angiosarcoma Global Clinical Trials Review, H2, 2018" provides an overview of Angiosarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Angiosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverag
Mon Feb 25, 2019 13:29
Urovant plans to use the proceeds to fund ongoing development of its lead compound vibegron, for business development opportunities, and for general corporate purposes. “This financing provides Urovant The post Urovant Sciences signs $100m debt financing deal with Hercules Capital appeared first on Pharmaceutical Business review.
Mon Feb 25, 2019 12:52
The FDA granted priority review and set a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2019. The application is supported by comprehensive data from The post FDA grants priority review and accepts sBLA of SOLIRIS as treatment for NMOSD appeared first on Pharmaceutical Business review.
Mon Feb 25, 2019 10:49
As part of an exclusive, global strategic collaboration and option agreement, AbbVie and Voyager will develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein to treat Parkinson’s The post AbbVie, Voyager sign $1.5bn gene therapy deal appeared first on Pharmaceutical Business review.
Mon Feb 25, 2019 10:49
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced the findings of a series of clinical cases investigating the combined use of SedLine® and O3® during cardiac surgery.
Mon Feb 25, 2019 09:00
FREMONT, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which...
Thu Feb 21, 2019 04:02
MORRIS PLAINS, N.J., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced...
Wed Feb 20, 2019 04:02
HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell announced that translational data from the completed Phase 1/2 clinical study of NiCord® were reported at the 2019 TCT Annual Meeting.
Sun Feb 24, 2019 00:45
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Celgene Corporation (NASDAQ:CELG). Bristol-Myers Squibb will commence mailing the joint proxy statement / prospectus to its stockholders on or about February 22. The Bristol-Myers Squibb Special Meeting of Stockholders is scheduled to take place on April 12, 2019 at 10
Fri Feb 22, 2019 23:49
NEUCHÂTEL, Suiza--(BUSINESS WIRE)--Novostia anuncia que ha recaudado 6,5 millones de francos suizos de inversores privados para hacer avanzar los ensayos clínicos de su válvula cardíaca mitral y aórtica disruptiva. Las valvulopatías cardíacas afectan a más de 100 millones de personas en todo el mundo. Cada año, cientos de miles de pacientes se someten a un reemplazo de la válvula cardíaca. Las tecnologías disponibles conllevan serias restricciones: medicamentos anticoagulantes de por vida o ree
Fri Feb 22, 2019 23:44
NEUCHÂTEL, Zwitserland--(BUSINESS WIRE)--Novostia kondigt aan dat het CHF 6,5 miljoen van particuliere investeerders heeft opgehaald om zijn aortaklep en mitralisklep naar klinische proeven te brengen. Wereldwijd treffen meer dan 100 miljoen mensen hartklepaandoeningen. Elk jaar ondergaan honderdduizenden patiënten een hartklepvervanging. De beschikbare technologieën brengen ernstige beperkingen met zich mee: levenslange anticoagulantia of verdere vervangingen vanwege de beperkte houdbaarheid v
Fri Feb 22, 2019 23:43
CHICAGO--(BUSINESS WIRE)--The American Society for Blood and Marrow Transplantation (ASBMT), a professional society dedicated to advancing the science and clinical care for patients who require blood and marrow transplants, today announced it has changed its name to the American Society for Transplantation and Cellular Therapy (ASTCT) in recognition of the rapid shift toward cellular therapies in this field of medicine. The ASTCT name will better reflect the organization’s commitment to serving
Fri Feb 22, 2019 23:17
COLUMBUS, Ohio--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Ohio?src=hash" target="_blank"gt;#Ohiolt;/agt;--As another example of Columbus’ commitment to talent attraction and public-private partnerships (P3), the City today announced it will host the Ohio Bioscience Career Fair – Central Ohio Regional Career Fair Monday, February 25, 2019, from 2 p.m. to 5 p.m. at Eastland-Fairfield Career and Technical Schools (located at Gahanna Lincoln High School), Clark Hall, 380 Granville St.,...
Fri Feb 22, 2019 22:41
BOSTON--(BUSINESS WIRE)--FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Fri Feb 22, 2019 21:51
DUBLIN--(BUSINESS WIRE)--The "The New Clinical Trial Regulation: Overview and Impact" conference has been added to ResearchAndMarkets.com's offering. This course will provide an essential understanding to help with compliance with the new regulation and associated implementing acts and other texts for carrying out clinical trials in the EU. Why You Should Attend The new EU Clinical Trial Regulation (536/2014) will replace the European Clinical Trials Directive (2001/20/EC). The new regulation w
Fri Feb 22, 2019 17:46
DUBLIN--(BUSINESS WIRE)--The "The New Clinical Trial Regulation: Overview and Impact" conference has been added to ResearchAndMarkets.com's offering. This course will provide an essential understanding to help with compliance with the new regulation and associated implementing acts and other texts for carrying out clinical trials in the EU. Why You Should Attend The new EU Clinical Trial Regulation (536/2014) will replace the European Clinical Trials Directive (2001/20/EC). The new regulation w
Fri Feb 22, 2019 17:42
DUBLIN--(BUSINESS WIRE)--The "Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-2 (IL-2) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple s
Fri Feb 22, 2019 15:34
Episodic Migraine Headache StudyUnhappy with the Pain and Inconvenience of Episodic Migraine Headaches?Consider Joining a Study of a Proposed New Type of Medicine.We’re enrolling participants in a study of the safety and tolerability of an investigational medication for people with episodic migraine headaches.
Thu Feb 21, 2019 00:00
BASEL, Switzerland--(BUSINESS WIRE)--Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every
Fri Feb 22, 2019 15:30
STAMFORD, Conn.--(BUSINESS WIRE)--Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer. Also known as cholangiocarcinoma, biliary tract c
Fri Feb 22, 2019 15:30
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2018. As of December 31, 2018, Odonate had $139.1 million in cash, compared to $198.1 million as of December 31, 2017. This decrease in cash resulted primarily from net cash used in operating and inves
Fri Feb 22, 2019 15:15
DUBLIN--(BUSINESS WIRE)--The "GABA Transaminase Inhibitor - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. GABA Transaminase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across GABA Transaminase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sou
Fri Feb 22, 2019 14:36
DUBLIN--(BUSINESS WIRE)--The "Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Leber's Hereditary Optic Neuropathy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped wit
Fri Feb 22, 2019 14:31
DUBLIN--(BUSINESS WIRE)--The "Glucagon Receptor Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Glucagon Receptor Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Glucagon Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources
Fri Feb 22, 2019 14:25
DUBLIN--(BUSINESS WIRE)--The "Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hospital Acquired Methicillin-Resistant Staphylococcus Aureus Infections development. Th
Fri Feb 22, 2019 14:19
DUBLIN--(BUSINESS WIRE)--The "Tetrahydrofolate Dehydrogenase Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Tetrahydrofolate Dehydrogenase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Tetrahydrofolate Dehydrogenase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action
Fri Feb 22, 2019 14:13
DUBLIN--(BUSINESS WIRE)--The "Muscarinic Agonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Muscarinic Agonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Muscarinic Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analys
Fri Feb 22, 2019 14:10
DUBLIN--(BUSINESS WIRE)--The "Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Idiopathic Thrombocytopenic Purpura development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data
Fri Feb 22, 2019 14:08
MONTRÉAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/amorchem?src=hash" target="_blank"gt;#amorchemlt;/agt;--Le 22 février 2019, NuChem Thérapeutique Inc., une organisation de recherche contractuelle (ORC) en découverte et développement du médicament, située à Montréal et spécialisée en services de chimie médicinale et de synthèse, annonce qu’elle a complété une transaction de rachat par ses cadres. Un groupe de cadres supérieurs, incluant Marc LeBel, Daniel Guay, Marc Janes et John...
Fri Feb 22, 2019 14:00
MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/amorchem?src=hash" target="_blank"gt;#amorchemlt;/agt;--NuChem Therapeutics Inc., a drug discovery and development contract research organization (CRO) located in Montreal and specializing in medicinal and synthetic chemistry services, has completed a successful Management Buyout transaction (“MBO”). Senior management of the company, comprised of Marc LeBel, Daniel Guay, Marc Janes and John Mancuso, acquired 95% of the voting shares...
Fri Feb 22, 2019 14:00
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the following upcoming investor conferences: 8th Annual SVB Leerink Healthcare Conference on Wednesday, February 27 at 11:00 a.m. ET. Barclays Global H
Fri Feb 22, 2019 14:00
DUBLIN--(BUSINESS WIRE)--The "KOL Perspectives: Adaptive Trial Designs in IBD" drug pipelines has been added to ResearchAndMarkets.com's offering. This KOL Insight briefing focuses on KOLs views of Adaptive trial designs in IBD. Questions topics Current challenges in IBD clinical trials Adaptive Phase II/III trial designs Guselkumab's Phase II/III trial in Crohn's disease Novel clinical trials in IBD Key Highlights Most KOLs highlighted that recruitment is the greatest challenge in IBD clinical
Fri Feb 22, 2019 10:58
Johnson & Johnson Innovation facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function. To date, Morphic The post Morphic Therapeutic enters into integrin research and development collaboration with Janssen appeared first on Pharmaceutical Business review.
Fri Feb 22, 2019 11:11
As per terms of the deal, Merck’s subsidiary will pay $5.85 per share to purchase all outstanding shares of Immune Design. Immune Design has next-generation in vivo approaches, The post Merck to buy late-stage immunotherapy firm Immune Design for $300m appeared first on Pharmaceutical Business review.
Fri Feb 22, 2019 11:11
Novostia Technology for Heart Valve Prosthesis Raises CHF 6.5 Million to Start First Clinical Trials
NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cardiacsurgery?src=hash" target="_blank"gt;#cardiacsurgerylt;/agt;--Novostia technology for heart valve prosthesis raises CHF 6.5 million to start first clinical trials
Fri Feb 22, 2019 09:30
NEUCHÂTEL, Schweiz--(BUSINESS WIRE)--Novostia meldet die Aufbringung von Finanzmitteln im Wert von 6,5 Mio. CHF von Privatinvestoren, um klinische Studien zu der disruptiven Aorten- und Mitralherzklappe des Unternehmens zu starten. Mehr als 100 Millionen Menschen sind weltweit von Herzklappenerkrankungen betroffen. Jedes Jahr müssen sich Hunderttausende von Patienten Verfahren zum Herzklappenersatz unterziehen. Die vorhandenen Technologien sind alle mit schwerwiegenden Einschränkungen verbunden
Fri Feb 22, 2019 09:30
NEUCHÂTEL, Suisse--(BUSINESS WIRE)--Novostia annonce avoir levé CHF 6.5 millions auprès d’investisseurs privés pour réaliser les premiers essais cliniques de sa valve cardiaque artificielle innovante. Les maladies des valves cardiaques affectent plus de 100 millions de personnes dans le monde. Chaque année des centaines de milliers de patients subissent un remplacement de valve cardiaque. Les technologies existantes induisent de sérieux inconvénients : prise de traitement anticoagulant à vie ou
Fri Feb 22, 2019 09:30
NEUCHÂTEL, Svizzera--(BUSINESS WIRE)--Novostia annuncia di aver raccolto 6,5 milioni di franchi svizzeri da investitori privati per proseguire con i trial clinici per le sue valvole cardiache aortica e mitrale. Le cardiopatie valvolari colpiscono oltre 100 milioni di persone in tutto il mondo. Ogni anno centinaia di migliaia di pazienti vengono sottoposti a una sostituzione valvolare. Le tecnologie disponibili comportano serie limitazioni: necessità di utilizzare medicinali anticoagulanti per t
Fri Feb 22, 2019 09:30
Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv The post Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure appeared first on Pharmaceutical Business review.
Fri Feb 22, 2019 09:07
We are currently seeking Teen participants (ages 12-17) with Juvenile Arthritis, to take part in a Usability Study being sponsored by a major medical company. The study will take place in mid-March and will require a parent or legal guardian to accompany the teen during the 1-hour study. The Study is to evaluate the usability of an Auto-Injector device. The study will involve handling a AI, and simulating an injection into a pad – participants will NOT actually perform an injection on themselves.Please...
Fri Feb 15, 2019 00:00
TAMPA, Fla. & STOCKHOLM--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/asco2017?src=hash" target="_blank"gt;#asco2017lt;/agt;--Founded by scientists at Sweden's Karolinska Institutet, Vycellix is establishing its headquarters adjacent to Moffitt Cancer Center in Tampa, Fla.
Thu Feb 21, 2019 22:00
DUARTE, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CityofHope?src=hash" target="_blank"gt;#CityofHopelt;/agt;--City of Hope announced that it has received its third lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute.
Thu Feb 21, 2019 19:00
Do you have bipolar disorder? Participate in a survey to help understand more about bipolar disorder. Participants must have been diagnosed, at least 5 years, with Bipolar Mania and Mixed Episodes and are on treatment.
Wed Feb 20, 2019 00:00
NEW YORK--(BUSINESS WIRE)--Bona Vida launches its global CBD platform, focused on developing a portfolio of product verticals in the animal and adult wellness space.
Thu Feb 21, 2019 16:15
DRAPER, Utah--(BUSINESS WIRE)--Hoopes Vision in Draper, Utah, is participating in the AcuFocus clinical study for the IC-8 intraocular lens designed for patients with cataracts.
Thu Feb 21, 2019 16:05
PRINCETON, N.J.--(BUSINESS WIRE)--Oyster Point Pharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Thu Feb 21, 2019 16:00
BERWYN, Pa.--(BUSINESS WIRE)--Complexa Inc. today announced dosing of the first patient in PRIMEx, a Phase 2 clinical trial evaluating the safety and efficacy of two doses of the company’s lead candidate, CXA-10, to treat pulmonary arterial hypertension (PAH). PAH is a rare, progressive disease characterized by high blood pressure in the vessels that carry blood from the right side of the heart to the lungs, which can compromise the normal function of the heart. It impacts approximately 30,000
Thu Feb 21, 2019 15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented new preclinical research on its MGTA-145 product candidate for stem cell mobilization at the Transplant and Cellular Therapy (TCT) annual meeting. Magenta is developing MGTA-145 as a first-line agent to enable single-day mobilization and collecti
Thu Feb 21, 2019 15:00
BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at...
Thu Feb 21, 2019 14:00
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:30 a.m. EST in New York, NY. A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An a
Thu Feb 21, 2019 14:00
CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)--MPM Capital, a life-sciences venture capital firm, raises $400 million to fund innovative early-stage therapeutics companies.
Thu Feb 21, 2019 14:00
BLACKSBURG, Va.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CD?src=hash" target="_blank"gt;#CDlt;/agt;--Landos Biopharma announced publication of findings that further elucidate the regulatory arm of the novel MOA for BT-11, its IND for CD & UC
Thu Feb 21, 2019 14:00
BURLINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and...
Thu Feb 21, 2019 14:00
KENILWORTH, N.J. & SEATTLE & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24IMDZ&src=ctag" target="_blank"gt;$IMDZlt;/agt; lt;a href="https://twitter.com/hashtag/IMDZ?src=hash" target="_blank"gt;#IMDZlt;/agt;--Merck to Acquire Immune Design
Thu Feb 21, 2019 13:45
Publication date: March 2019Source: Contemporary Clinical Trials, Volume 78Author(s):
Thu Feb 21, 2019 14:06
Publication date: April 2019Source: Contemporary Clinical Trials, Volume 79Author(s): Jonathan Myers, Holly Fonda, Minal Vasanawala, Kieran Chung, George Segall, Khin Chan, Patricia NguyenAbstractCardiovascular disease (CVD) currently claims nearly one million lives yearly in the US, accounting for nearly 40% of all deaths. Coronary artery disease (CAD) accounts for the largest number of these deaths. While efforts aimed at treating CAD in recent decades have concentrated on surgical and catheter-based...
Sat Mar 02, 2019 20:21
Publication date: April 2019Source: Contemporary Clinical Trials, Volume 79Author(s): Michael S. Gordon, Frank J. Vocci, Faye Taxman, Marc Fishman, Bikash Sharma, Thomas R. Blue, Kevin E. O'GradyAbstractBackgroundBuprenorphine can be effective in a variety of community substance use treatment settings outside of methadone programs, including outpatient programs and medical practices. In these settings, it has been found to be effective in reducing opioid use and retaining patients in treatment. Despite...
Tue Feb 26, 2019 14:24
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna today announced the addition of three industry veterans to the Company’s management team to support continued growth.
Thu Feb 21, 2019 13:30
HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell reported new data from its NAM-NK and NiCord® programs that were presented at the 2019 TCT Annual Meeting.
Thu Feb 21, 2019 13:00
HTL0030310 is a potent and selective agonist of the SSTR5 (somatostatin 5) receptor and the sixth molecule designed by the Company using its GPCR Structure-Based Drug Design (SBDD) The post Sosei Heptares doses first patient in trial targeting endocrine disorders appeared first on Pharmaceutical Business review.
Thu Feb 21, 2019 12:31
Sandoz will market the authorized generic version of Suboxone on behalf of Indivior in the country. Indivior said its decision is based on the market impact expected from The post Indivior introduces generic version of Suboxone opioid drug in US appeared first on Pharmaceutical Business review.
Thu Feb 21, 2019 12:31
Subject to approval by various courts, the stipulated order from the FTC will block Teva from engaging in reverse-payment patent settlement agreements that would hinder consumer access to The post FTC, Teva reach global settlement to resolve reverse-payment charges appeared first on Pharmaceutical Business review.
Thu Feb 21, 2019 12:31
The financing was led by RA Capital Management and was joined by new investors including Eventide Asset Management, Biotechnology Value Fund, OrbiMed, EcoR1 Capital, Vida Ventures, Curative Ventures The post Peloton Therapeutics secures $150m in Series E financing appeared first on Pharmaceutical Business review.
Thu Feb 21, 2019 10:27
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early...
Fri Feb 15, 2019 07:02
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου